AngioDynamics, Inc.
NASDAQANGO heads into the back half of fiscal 2026 with fresh analyst conviction behind it — two buy-side target upgrades on the day of results, a stock now up 7% on the month, and options markets suddenly demanding far more downside protection than they have all year. The analyst story is the clearest positive signal this week. Both HC Wainwright and Canaccord Genuity raised their price…
Snapshot as of 2 Aug 2026
ANGO heads into the back half of fiscal 2026 with fresh analyst conviction behind it — two buy-side target upgrades on the day of results, a stock now up 7% on the month, and options markets suddenly demanding far more…
AngioDynamics heads into its July 13 quarterly print with shorts quietly unwinding and the Street holding a cautious optimism that the stock's 13% monthly rebound has yet to fully validate. The sharpest trend in…
AngioDynamics enters the week with a notable gap between where the stock trades and where analysts think it belongs — and the market's short positioning has started to quietly reflect that divergence. Short sellers…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for ANGO — free to start on ORTEX.
Sign up for free →Open ANGO on ORTEX